Sector: Health Care.Industry: Biotechnology
Viracta Therapeutics Inc is a clinical-stage, biomarker-directed precision oncology company focused on advancing new medicines for the treatment of virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma.

Earnings

see more
Q1 2021Est.ActualSurprise
EPS
(EXPECTED)2021-05-02
REV

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
VIRXViracta Therapeutics0%

Viracta Therapeutics Company Questions & Answers

Q

How do I buy Viracta Therapeutics (VIRX) stock?

A

You can purchase shares of Viracta Therapeutics (NASDAQ: VIRX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Viracta Therapeutics's (VIRX) main competitors?

A

Other companies in Viracta Therapeutics’s space includes: Neurocrine Biosciences (NASDAQ:NBIX), CureVac (NASDAQ:CVAC) and Amgen (NASDAQ:AMGN).

Q

What is the target price for Viracta Therapeutics?

A

The latest price target for Viracta Therapeutics (NASDAQ: VIRX) was reported by Evercore ISI Group on 2021-03-25. The analyst firm set a price target for 45.00 expecting VIRX to rise to within 12 months (a possible 471.07% upside). 1 analyst firms have reported ratings in the last year.

Q

How much is Viracta Therapeutics (VIRX) stock ?

A

The stock price for Viracta Therapeutics (NASDAQ: VIRX) is $7.88 last updated Today at 8:00:02 PM.

Q

When is the next Viracta Therapeutics (VIRX) dividend?

A

There are no upcoming dividends for Viracta Therapeutics.

Q

When is Viracta Therapeutics (NASDAQ:VIRX) reporting earnings?

A
Viracta Therapeutics’s Q1 earnings are confirmed from now on May 2, 2021.
Q

When is the upcoming split for VIRX?

A

There is no upcoming split for Viracta Therapeutics.